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Sir,
The National Institute for Clinical Excellence (NICE) guidelines
for the use of irinotecan, oxaliplatin and raltitrexed in the
treatment of patients with advanced colorectal cancer were
published in March 2002 (NICE, 2002). In summary, they
recommended the use of second-line irinotecan following
failure of 5-fluorouracil (5FU) and folinic acid (FA), but
withheld their decision on the use of first-line combination
chemotherapy until the results of the MRC CR08/FOCUS trial were
available.
FOCUS is a five-arm trial assessing whether combination
chemotherapy (the modified de Gramont (MdG) schedule of
5FU/FA+irinotecan, or MdG+oxaliplatin) should be given
first-line, or second-line following the failure of single-
agent MdG. The control arm is first-line MdG followed, at
relapse, by single-agent irinotecan, now the NICE approved UK
standard.
In June 2002, an editorial in the British Journal of Cancer
(Saunders and Valle, 2002) and a letter to the Daily Telegraph
(Cunningham et al, 2002) criticised the NICE recommendations,
on the grounds that there was already sufficient evidence to
recommend first-line combination chemotherapy. This has im-
plications for the FOCUS study, as two-thirds of patients entering
the trial initially receive single-agent MdG. It is disappointing,
given the potential damage to an open MRC trial, that the concerns
expressed in your editorial had not been made known to any of the
groups involved with its conduct. All MRC funded trials are
regularly reviewed by an independent Data Monitoring and Ethics
Committee (DMEC), who report to a Trial Steering Committee
(TSC), which includes an independent chair and members. The
DMEC and TSC are independent of the FOCUS management group
and NICE. The role of these committees is to ensure that MRC
trials remain valid in the face of emerging evidence from other
studies, and are not open to the criticisms of being unethical,
outdated or irrelevant. The editorial implied, we hope unin-
tentionally, that these responsibilities had not been met in respect
of FOCUS.
As independent members of the TSC, we wish to state that
FOCUS remains a valid study, and that on the evidence available
patients in this trial are not being disadvantaged. This evidence is
as follows:
THE DMEC REPORT
The DMEC for the FOCUS trial met on 14 June 2002, when 1006 of
the planned 2100 patients had been entered. In making their
recommendations, they considered not only the interim FOCUS
data but also all the relevant external evidence. They reported to
the TSC that there were no safety or ethical reasons to close or
materially change the design of the trial.
To further reassure clinicians and patients, the TSC have agreed
to release the information that the current overall median survival
for patients in the FOCUS trial is 16 months, which compares
favourably with the best arms of most recent randomised trials in
this illness (de Gramont et al, 2000; Douillard et al, 2000; Saltz et al,
2000).
EXTERNAL EVIDENCE
Although two trials comparing first-line 5FU+irinotecan with 5FU
alone showed a significant survival benefit with the combination
chemotherapy (Douillard et al, 2000; Saltz et al, 2000), there are
difficulties with extrapolating the results of both of these. Firstly,
combination chemotherapy causes increased toxicity, and the
doses of treatment used in the Saltz trial (Saltz et al, 2000) had to
be reduced in a subsequent study owing to unacceptable toxicity
(Rothenberg et al, 2001; Sargent et al, 2001). Secondly, the control
arms might not be optimal. The Mayo Clinic 5FU/FA schedule was
used in one trial (Saltz et al, 2000), which is known to be
suboptimal (de Gramont et al, 1997), and in neither trial was there
a specified second-line treatment. It is questionable whether the
survival benefits would have been seen, had a control arm been
used of the type employed in FOCUS.
Other recent studies are also difficult to extrapolate. Although
the Tournigand trial (Tournigand et al, 2001) reported impressive
median survival, this may have been because of patient selection as
a first-line single-agent control arm was not included. Two further
trials reported at ASCO this year (Goldberg et al, 2002; Grothey
et al, 2002) do not clarify the situation owing to their design, for
*Correspondence: Professor M Mason;
E-mail: malcolm.mason@velindre-tr.wales.nhs.uk
Alternatively, Professor Richard Stevens, E-mail: Richard.Stevens@ctu.mrc.
ac.uk, Tel: +44 20 76704737; fax: +44 20 73704818, who handled the
initial correspondence on behalf of the authors.
British Journal of Cancer (2003) 88, 1152 – 1155
& 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00
www.bjcancer.comexample comparing infusional 5FU/FA+oxaliplatin with bolus
5FU/FA+irinotecan.
As NICE has now approved irinotecan as second-line therapy,
there is a concern that in FOCUS the crossover for patients will be
asymmetric. Patients initially having oxaliplatin could expect to
crossover (i.e. receive irinotecan as salvage therapy), whereas those
initially on irinotecan would not be able to crossover to oxaliplatin,
as it is not licensed or approved in this indication. To address this
situation the Trial Management Group (TMG) has suggested that,
in those patients fit enough to receive it, a planned crossover
treatment be designed. The TSC approved this request at their
meeting on 19th June, and this will be implemented as soon
as possible. This will ensure that every patient entering FOCUS
will potentially have access to irinotecan and oxaliplatin at some
point.
The TSC, DMEC and TMG believe that FOCUS remains a key
trial despite the studies quoted in your editorial. We support its
continued accrual, and encourage existing participants and new
centres to enter patients. Only in this way can we clarify the use
and sequencing of combination chemotherapy as quickly as
possible.
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Sir,
In our editorial ‘Why hasn’t the National Institute been NICE to
patients with colorectal cancer’, we highlighted the disparity of
treatment in England and Wales compared to other industrialised
countries, particularly with respect to the poor 5-year survival
figures. Our concerns focused on the conclusions reached by the
NICE panel in the face of two prospective, randomised trials
involving more than 1000 patients showing a survival advantage in
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